Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Dr Barry Kenny joins Heptares Therapeutics

This article was originally published in Scrip

Executive Summary

Heptares Therapeutics, a UK drug discovery company focused on G-protein-coupled receptor targets, has appointed Dr Barry Kenny chief business officer. He will focus on business development and strategic alliances, based on the company's drug discovery capabilities and its StaR technology. He has more than 24 years' research and management experience in the pharmaceutical and biotechnology industries, having most recently served as vice-president of drug discovery at Takeda Cambridge. Prior to that, he was commercial director at Paradigm Therapeutics.

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC004912

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel